Form 4: Director Schmidt Sells ASTH Shares After Option Exercise

Astrana Health Director David Schmidt exercised stock options and subsequently sold 20,000 shares back to the issuer.

Summary

• Director David Schmidt exercised 20,000 stock options for Astrana Health, Inc. (ASTH) common stock at an exercise price of $18.20 per share.
• These stock options were fully vested and exercisable, with an expiration date of November 11, 2025.
• Concurrently, Schmidt disposed of 20,000 shares of common stock at a price of $27.76 per share.
• The disposition of shares was a repurchase by the Issuer.
• Following these transactions, David Schmidt beneficially owns 15,763 shares of Astrana Health common stock.
• The remaining beneficial ownership includes 6,449 shares of restricted stock, which will vest on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine insider transaction involving an option exercise and subsequent sale, often pre-planned for liquidity or diversification. The repurchase by the issuer could be seen as a positive for capital management.

Positives

• Director David Schmidt realized a profit by exercising stock options at $18.20 and selling the shares at $27.76.

Negatives

• Director David Schmidt sold 20,000 shares of common stock, which were repurchased by the Issuer.
• The total beneficial ownership of common stock by Director Schmidt decreased from an implied 35,763 shares (post-exercise, pre-sale) to 15,763 shares.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The Issuer repurchased 20,000 shares of common stock from Director David Schmidt.

Stakeholder Impact

• Shareholders: The repurchase of shares by the issuer can reduce the number of outstanding shares, potentially increasing earnings per share for remaining shareholders. The director's sale might be viewed neutrally or slightly negatively depending on market perception.

Next Steps

• Vesting of 6,449 shares of restricted stock on the earlier of June 11, 2026, or the Issuer's 2026 annual meeting of stockholders.

Key Dates

Recommendation

The filing reports an insider transaction where a director exercised options and sold shares back to the company. This is a routine event for directors managing their equity compensation. While a sale, it is not necessarily a strong negative signal, especially if pre-planned under a Rule 10b5-1 plan. The company's repurchase of shares can be seen as a positive for capital management. Without further context on the company's performance or strategic direction, a 'Hold' recommendation is appropriate as this filing alone does not provide sufficient information for a strong buy or sell signal.

Keywords

Astrana Health, ASTH, Form 4, Insider Transaction, Stock Options, Director Sale, Share Repurchase